Efficacy and safety of sofosbuvir/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: A meta-analysis

doi:10.4254/wjh.v14.i6.1248

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4460)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

185

WORD

HTML

2078

Figures (1-3)

510

Tables (1-2)

349

Sum=3157

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

325

Download

978

Sum=1303

Jun 27, 2022 (publication date) through Nov 22, 2024

Times Cited of This Article

Times Cited (13)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Hepatol. Jun 27, 2022; 14(6): 1248-1257
Published online Jun 27, 2022. doi: 10.4254/wjh.v14.i6.1248

Table 1 Baseline characteristics of included studies

Ref.	Study design	Sample size (n)	Age	Subtypes (3A/3B), (%)	Co-infection with HIV (%)	Baseline NS5A RAS (%)	Prior treatment (%)	SVR12 ITT (%)	SVR12 PP (%)	Treatment-related adverse event (%)
Pianko et al[22], 2015	RCT	52	I: 54.0 (44-65); C: 56 (45-68)	NR	0	NR	I: 100.0; C: 100.0	I: 96.2; C: 88.5	I: 96.2; C: 88.5	NR
Esteban et al[16], 2018	RCT	204	I: 51 ± 7.6; C: 51 ± 7.3	I: 100.0/0.0; C: 99.0/1.0	I: 15.5; C: 13.9	I: 21.8; C: 19.4	I: 27.2; C: 26.7	I: 96.1; C: 91.1	I: 96.1; C: 92.0	I: 4.9; C: 1.0
von Felden et al[23], 2018	Cohort study	65	NR	NR	I: 2.9; C: 13.3	I: 11.4; C: 0.0	I: 37.1; C: 23.3	I: 100.0; C: 96.7	NR	NR
Drysdale et al[26], 2019	Cohort study	414	NR	NR	NR	NR	NR	NR	I: 98.0; C: 91.7	NR
Pasulo et al[27], 2019	Cohort study	130	NR	NR	NR	NR	NR	NR	I: 93.9; C: 98.4	NR
Hlaing et al[24], 2019	Cohort study	60	NR	NR	NR	NR	NR	NR	I: 100.0; C: 96.0	I: 31.4; C: 8.0
Wong et al[30], 2020	Cohort study	163	NR	NR	NR	NR	NR	I: 97.8; C: 97.5	I: 97.8; C: 97.5	NR

HIV: Human immunodeficiency virus; NS5A: Non-structural protein 5A; RAS: Resistance-associated substitution; SVR12: Sustained virological response 12 wk post treatment; ITT: Intention-to-treat; PP: Per-protocol; RCT: Randomized controlled trial; I: Intervention (sofosbuvir/velpatasvir + ribavirin), C: Control (sofosbuvir/velpatasvir), NR: Not reported.

Table 2 Subgroup analysis

Outcome	Subgroup		No. of studies	Effect size (RR with 95%CI)	I²
SVR12 (ITT analysis)	Overall		4	1.03 (0.99-1.07)	0
	Study design	RCT	2	1.06 (0.99-1.13)	0
	Study design	Non-RCT	2	1.01 (0.97-1.06)	0
	Effect estimates	Fixed model	4	1.04 (1.00-1.08)	0
	Effect estimates	Odd’s ratio	4	2.32 (0.91-5.89)	0
SVR12 (PP analysis)	Overall		6	1.03 (0.99-1.07)	48
	Study design	RCT	2	1.06 (1.00-1.13)	0
	Study design	Non-RCT	4	1.02 (0.97-1.07)	65
	Publication type	Full-text	4	1.00 (0.96-1.04)	0
	Publication type	Abstract	2	0.99 (0.88-1.10)	86
	Effect estimates	Fixed model	6	1.04 (1.01-1.07)	48
	Effect estimates	Odd’s ratio	6	2.36 (1.07-5.19)	14

SVR12: Sustained virological response 12 wk post treatment; ITT: Intention-to-treat; PP: Per-protocol; RCT: Randomized controlled trial.

Citation: Loo JH, Xu WXF, Low JT, Tay WX, Ang LS, Tam YC, Thurairajah PH, Kumar R, Wong YJ. Efficacy and safety of sofosbuvir/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: A meta-analysis. World J Hepatol 2022; 14(6): 1248-1257
URL: https://www.wjgnet.com/1948-5182/full/v14/i6/1248.htm
DOI: https://dx.doi.org/10.4254/wjh.v14.i6.1248